

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	D
Price	\$0.61
Change (%)	▼ 0.02 (3.17%)
Volume	322,536
52 Week Low	\$0.51
Market Cap	\$17,382,443
Rolling EPS	-1.33
PE Ratio	N/A
Shares Outstanding	28,356,351

Data as of 03/23/18 4:00 p.m. ET



Recent Headlines & Events

03/19/18 - 8:00 a.m.
Fibrocell Reports 2017 Financial Results and Recent Highlights

Date	Title
04/17/18	Alliance for Regenerative Medicine — 6th Annual Cell & Gene Therapy Investor Day

03/12/18 - 8:00 a.m.

Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights

03/06/18 - 8:01 a.m.

Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

Location New York, NY

04/25/18 2:00 p.m. ET

8th Annual World Orphan Drug Congress USA 2018

Location Oxon Hill, MD – Washington, DC metro area

05/19/18

International Investigative Dermatology 2018

Location Rosen Shingle Creek Resort
Orlando, Florida

SEC Filings

Filing Date	Form
03/19/18	PRE 14A
03/19/18	10-K
03/19/18	8-K
03/06/18	8-K

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	41	8.15	44.3	12,560,250
Mutual Fund	13	.26	1.4	401,600
Director and Officer	1	.25	0.4	105,600

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	8,267,413	29.2	2,727,273	12/31/17
Sabby Management, LLC	1,128,588	4.0	1,128,588	12/31/17
MSD Partners, L.P.	692,960	2.4	0	12/31/17
Armistice Capital LLC	613,896	2.2	613,896	12/31/17
Anson Funds Management LP.	448,136	1.6	448,136	12/31/17
The Vanguard Group, Inc.	267,280	0.9	-61,296	12/31/17
FNY Partners Fund LP	200,000	0.7	200,000	12/31/17
Point72 Asset Management, L.P.	200,000	0.7	200,000	12/31/17

Renaissance Technologies LLC	128,796	0.5	10,032	12/31/17
Creative Planning, Inc.	93,090	0.3	32,000	12/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.